Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 5Oxaliplatin 5Leucovorin 5Magnetic Resonance Spectroscopy 4Fluorouracil 4Erlotinib Hydrochloride 4Biopsy 4Trastuzumab 3Capecitabine 3dehydroftorafur 2cobimetinib 2atezolizumab 2Sorafenib 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2MK 2206 2Lapatinib 2Interleukin-12 Subunit p35 2Gemcitabine 2Chemotherapy, Adjuvant 2varlilumab 1trametinib 1tipifarnib 1sargramostim 1peposertib 1pembrolizumab 1motexafin lutetium 1ixabepilone 1entinostat 1cediranib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gallbladder Neoplasms × Radiation Dose Hypofractionation × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡